NCT05645536 2026-01-12Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyTolmar Inc.Phase 3 Enrolling by invitation250 enrolled
NCT03099174 2025-06-24This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerBoehringer IngelheimPhase 1 Completed133 enrolled 26 charts